These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33026078)

  • 1. Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn's Disease.
    Zhuang X; Tian Z; Feng R; Li M; Li T; Zhou G; Qiu Y; Chen B; He Y; Chen M; Zeng Z; Zhang S
    Inflamm Bowel Dis; 2020 Oct; 26(11):1636-1647. PubMed ID: 33026078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Faecal Microbiota in Paediatric Crohn's Disease and Their Dynamic Changes During Infliximab Therapy.
    Wang Y; Gao X; Ghozlane A; Hu H; Li X; Xiao Y; Li D; Yu G; Zhang T
    J Crohns Colitis; 2018 Feb; 12(3):337-346. PubMed ID: 29194468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease.
    Wang Y; Gao X; Zhang X; Xiao F; Hu H; Li X; Dong F; Sun M; Xiao Y; Ge T; Li D; Yu G; Liu Z; Zhang T
    Gut Microbes; 2021; 13(1):1-18. PubMed ID: 33430702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease.
    Ventin-Holmberg R; Eberl A; Saqib S; Korpela K; Virtanen S; Sipponen T; Salonen A; Saavalainen P; Nissilä E
    J Crohns Colitis; 2021 Jun; 15(6):1019-1031. PubMed ID: 33300552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
    Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
    World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
    Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of mucosa-associated gut microbiota during treatment in Crohn's disease.
    He C; Wang H; Liao WD; Peng C; Shu X; Zhu X; Zhu ZH
    World J Gastroenterol; 2019 May; 25(18):2204-2216. PubMed ID: 31143071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
    Hendler SA; Cohen BL; Colombel JF; Sands BE; Mayer L; Agarwal S
    J Crohns Colitis; 2015 Mar; 9(3):266-75. PubMed ID: 25540149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease.
    Rajca S; Grondin V; Louis E; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Paintaud G; Piver E; Allez M; Mary JY; Sokol H; Colombel JF; Seksik P
    Inflamm Bowel Dis; 2014 Jun; 20(6):978-86. PubMed ID: 24788220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
    Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.
    Davidov Y; Ungar B; Bar-Yoseph H; Carter D; Haj-Natour O; Yavzori M; Chowers Y; Eliakim R; Ben-Horin S; Kopylov U
    J Crohns Colitis; 2017 May; 11(5):549-555. PubMed ID: 28453755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiles and interactions of gut microbiome and intestinal microRNAs in pediatric Crohn's disease.
    Lv Y; Zhen C; Liu A; Hu Y; Yang G; Xu C; Lou Y; Cheng Q; Luo Y; Yu J; Fang Y; Zhao H; Peng K; Yu Y; Lou J; Chen J; Ni Y
    mSystems; 2024 Sep; 9(9):e0078324. PubMed ID: 39150251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic monitoring of infliximab therapy in Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila PE; Sipponen T; Färkkilä MA
    Inflamm Bowel Dis; 2011 Apr; 17(4):947-53. PubMed ID: 20860048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is mean platelet volume a good predictor of sustained response to one year infliximab therapy in pediatric patients with Crohn's disease?
    Herman R; Sładek M; Pieczarkowski S; Dumnicka P; Fyderek K
    Folia Med Cracov; 2017; 57(2):63-71. PubMed ID: 29121038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of early remission after infliximab in Crohn's disease using baseline microbiome and metabolomics.
    Guo Y; Wu X; Wang Y; Zeqian Y; Cao L; Zhu F
    J Pharm Biomed Anal; 2024 Dec; 251():116424. PubMed ID: 39180897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
    Dreesen E; Van Stappen T; Ballet V; Peeters M; Compernolle G; Tops S; Van Steen K; Van Assche G; Ferrante M; Vermeire S; Gils A
    Aliment Pharmacol Ther; 2018 Feb; 47(3):346-355. PubMed ID: 29226370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Long-term Clinical and Endoscopic Remission in Children With Crohn Disease Treated With Infliximab.
    D'Arcangelo G; Oliva S; Dilillo A; Viola F; Civitelli F; Isoldi S; Cucchiara S; Aloi M
    J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):841-846. PubMed ID: 30633110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early serum infliximab trough level and mucosal healing could be predictors for one-year outcome after initiating therapy in Crohn's disease.
    Tang J; Yang Q; Huang Z; Guo H; Chao K; Hu P; Gao X
    Scand J Gastroenterol; 2020 Sep; 55(9):1035-1040. PubMed ID: 32819192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn's disease patients in western China.
    Song X; Zhang H; Song J; Wang H; Guo H; Zhou X
    Clin Exp Med; 2024 Oct; 24(1):237. PubMed ID: 39365401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal microbiota composition is linked to the postoperative disease course in patients with Crohn's disease.
    Strömbeck A; Lasson A; Strid H; Sundin J; Stotzer PO; Simrén M; Magnusson MK; Öhman L
    BMC Gastroenterol; 2020 May; 20(1):130. PubMed ID: 32366222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.